What are the odds of developing cannabis use disorder?
Evidence quality 4.75/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, US adult
1 in 16
6.3% lifetime chance
Most people underestimate this.
range 1 in 25 to 1 in 11
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Cannabis occupies an unusual position in public risk perception: it is widely regarded as the drug least likely to cause dependence, often in explicit contrast to alcohol, opioids, or stimulants. The political framing of legalization debates has reinforced this view — advocates have emphasized relative safety compared to alcohol, and the term "marijuana use disorder" does not have the cultural salience of "alcoholism" or "opioid addiction." Many users and non-users alike believe cannabis is simply not addictive in any meaningful sense. That belief is incorrect for a substantial minority of users. The post-2018 legalization wave has also made high-potency products — concentrates, edibles, and vapes with THC concentrations far above what was available in prior decades — the norm in legal markets, changing the pharmacological exposure profile in ways that older survey data may not fully capture.
Rough estimate: ~1-2% of adults
Source: editorial intuition, not polled
Actual
6.3% of US adults meet DSM-5 criteria for cannabis use disorder at some point in their lifetime (NESARC-III, 2012–2013)
US adults aged 18 and older (NESARC-III, N=36,309, face-to-face interviews 2012–2013)
Show derivation
Hasin et al. (American Journal of Psychiatry, 2016) used the NESARC-III data (N=36,309 US adults, 2012–2013) with DSM-5 diagnostic criteria to estimate lifetime cannabis use disorder prevalence at 6.3% and 12-month prevalence at 2.5%. The lifetime figure is used directly as the normalized estimate: it already represents the US adult population and encompasses the full adult lifespan captured by retrospective structured interviews. Among adults who have ever used cannabis, the conditional probability of developing CUD is substantially higher. The Lopez-Quintero et al. (2011, Drug and Alcohol Dependence) analysis of NESARC-I data found that approximately 8.9% of ever-users transition to cannabis dependence — the per-user conditional rate. The NESARC-III all-adult 6.3% figure is used here because the question asks about population-level lifetime risk for a US adult, not conditional risk given use. SAMHSA 2024 NSDUH found 20.6 million past-year CUD among US residents 12+, consistent with the high end of prevalence estimates once cannabis use rates are applied.
Caveats: The 6.3% lifetime prevalence is drawn from 2012-2013 NESARC-III data, before leg…
The 6.3% lifetime prevalence is drawn from 2012-2013 NESARC-III data, before legalization in most US states. Since 2018, both cannabis use prevalence and use disorder rates have increased substantially; SAMHSA 2024 found 20.6 million past-year CUD cases, suggesting the lifetime prevalence for today's younger cohort will be higher than 6.3% by the time they reach the age of the NESARC-III respondents. The conditional risk among ever-users is substantially higher than the all-adult 6.3% — approximately 8.9% of ever-users develop dependence, per Lopez-Quintero et al. (2011, Drug and Alcohol Dependence, NESARC-I data). Post-legalization products — concentrates, vapes, and edibles with THC concentrations of 40-90% versus the 5-10% of typical cannabis sold in 2000 — represent a meaningfully different pharmacological exposure than the products used by most NESARC-III respondents. The 6.3% figure should be treated as a lower bound for current and future adult cohorts. DSM-5 CUD requires at least 2 of 11 criteria; tolerance and withdrawal are included but not required, meaning the disorder captures a wider range of problematic use patterns than colloquial "addiction."
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Compulsive sexual behavior
What are the odds of developing compulsive sexual behavior disorder?
Benzo dependence
What are the odds of developing benzodiazepine dependence after a standard prescription?
Opioid addiction
What are the odds of developing opioid addiction after a standard surgical prescription?
Bipolar disorder
What are the odds of developing bipolar disorder at some point in your lifetime?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The 2012–2013 NESARC-III (the same nationally representative study of 36,309 US adults that established the 29.1% lifetime prevalence of alcohol use disorder) found a 6.3% lifetime prevalence of DSM-5 cannabis use disorder (Hasin et al., American Journal of Psychiatry, 2016). The 12-month prevalence was 2.5%. SAMHSA’s 2024 National Survey on Drug Use and Health found 20.6 million Americans with past-year cannabis use disorder, making it the most common drug use disorder in the United States, more common than opioid use disorder (4.8 million) and stimulant use disorder (4.3 million) combined. The 6.3% lifetime figure is almost certainly a floor rather than a ceiling: it predates the 2018 legalization wave that transformed access and product potency across most of the country, and both cannabis use and cannabis use disorder rates have risen since 2012–2013.
The perception that cannabis is simply not addictive holds up poorly against the diagnostic data. The DSM-5 criteria for cannabis use disorder (which include tolerance, withdrawal, unsuccessful efforts to cut down, continued use despite interpersonal or occupational problems, and giving up important activities for cannabis) map directly onto the patterns that heavy daily users typically describe, often without having thought of themselves as disordered. Among ever-users, the conditional probability of developing disorder is approximately 8–9%, based on NESARC-I data (Lopez-Quintero et al., 2011). That per-user rate is lower than for nicotine (~67%) and heroin (~23%) but higher than alcohol (~15%) and cocaine (~17%), a ranking that conflicts sharply with the cultural hierarchy of drug danger. The post-legalization shift to high-potency concentrates and vapes (with THC concentrations of 40–90% versus the 5–10% typical of 2000-era cannabis) changes the exposure profile in ways that older survey data cannot capture.
The 6.3% all-adult lifetime figure encompasses a wide range of users. The disorder is far more common among those who begin using before age 18 (where adolescent brain development creates higher vulnerability), daily or near-daily users, and those with co-occurring anxiety or mood disorders — for whom cannabis is frequently used for self-medication of insomnia and anxiety. Occasional users (monthly or less) face a substantially lower conditional risk than the all-adult estimate implies. Men have higher rates than women in the NESARC-III data, consistent with higher rates of heavy use in male cohorts. The 6.3% figure also includes resolved cases: people who met criteria during periods of heavier use and later reduced or stopped without formal treatment, which is common. DSM-5 CUD requires only two of eleven criteria, spanning a severity range from mild functional impairment to severe dependence.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] Hasin DS et al. — American Journal of Psychiatry, 2016 — Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions–III
Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions–III- Statistic
Lifetime and 12-month prevalences of DSM-5 cannabis use disorder among US adults were 6.3% and 2.5%, respectively (NESARC-III, N=36,309)- Excerpt
“"The prevalences of 12-month and lifetime cannabis use disorder were 2.5% and 6.3%. Odds of 12-month and lifetime cannabis use disorder were higher for men, Native Americans, unmarried individuals, those with low incomes, and young adults; cannabis use disorder was associated with other substance use disorders, affective disorders, anxiety, and personality disorders." ”
- Source data from
- 2016-03-01
- Accessed
- 2026-05-04 · archived copy
- Calculation
- The 6.3% lifetime prevalence is used directly as the native numerator (6.3 per 100 US adults). This is the primary calculation input, representing the first nationally representative DSM-5 CUD prevalence estimate using structured diagnostic interviews. The 2.5% 12-month figure confirms the disorder is active for many adults at any given time, not merely historical.
- Independence
- NESARC-III was conducted by NIAAA using probability sampling and structured clinical interviews (AUDADIS-5), methodologically distinct from SAMHSA NSDUH self-report instruments.
-
[2] Hasin DS et al. — JAMA Psychiatry, 2015 — Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013
Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013- Statistic
Past-year prevalence of DSM-IV marijuana use disorder increased from 1.5% in 2001-2002 to 2.9% in 2012-2013; marijuana use more than doubled over the same period- Excerpt
“"The past-year prevalence of marijuana use was 4.1% in 2001-2002 and 9.5% in 2012-2013. The past-year prevalence of DSM-IV marijuana use disorder was 1.5% in 2001-2002 and 2.9% in 2012-2013 (P < .05). Significant increases were found across all demographic subgroups." ”
- Source data from
- 2015-12-01
- Accessed
- 2026-05-04 · archived copy
- Calculation
- This study uses DSM-IV criteria and past-year prevalence, so the absolute figures are lower than the DSM-5 lifetime estimates in Hasin et al. 2016. It is used here to establish the trend: both cannabis use and cannabis use disorder have increased substantially since 2001-2002, with disorder prevalence roughly doubling. The post-legalization era (2018 onward) is not captured in either NESARC study and likely represents a further increase in exposure and conditional disorder rates.
- Independence
- Both Hasin 2015 (JAMA Psychiatry) and Hasin 2016 (Am J Psychiatry) draw on NESARC wave data. They are not fully independent sources but use different diagnostic criteria (DSM-IV vs DSM-5) and different comparison years, providing genuine methodological triangulation on the trend.
-
[3] Substance Abuse and Mental Health Services Administration (SAMHSA) — Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health
Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and HealthSee all 3 Likelier entries citing this source →
- Statistic
20.6 million people aged 12 or older had past-year cannabis use disorder in 2024, making it the most common drug use disorder in the US- Excerpt
“"Marijuana use disorder was the most common drug use disorder (20.6 million), followed by opioid use disorder (4.8 million) and central nervous system stimulant use disorder (4.3 million). In 2024, 44.3 million individuals reported marijuana use in the past month." ”
- Source data from
- 2025-07-14
- Accessed
- 2026-05-04 · archived copy
- Calculation
- SAMHSA 2024 NSDUH: 20.6M past-year CUD / ~260M US adults ≈ 7.9% past-year CUD prevalence. This figure is notably higher than the NESARC-III 2.5% 12-month estimate, reflecting both the increase in cannabis use since 2012-2013 and instrument differences between NSDUH and NESARC. It is used here as a cross-validation anchor showing that post-legalization cannabis use disorder rates are higher than the NESARC-III figures, supporting the upper end of the uncertainty range. The 6.3% lifetime estimate from 2012-2013 is almost certainly an undercount for today's adult cohort.